Downregulation of TNF and JAK-STAT results in clinical benefits, including reduced inflammation and cellular senescence, increase in healthy tissue homeostasis, and improved outcomes for myopathies, rheumatoid arthritis, liver diseases, and cancer [69–71]. This evidence concerns the gene SOAT1 and myopathy.